Income Statement Fisher & Paykel Healthcare Corporation Limited
Equities
FPH
NZFAPE0001S2
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.03 NZD | -0.96% | +1.28% | +61.14% |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.26B | 1.97B | 1.68B | 1.58B | 1.74B | |||||
Total Revenues | 1.26B | 1.97B | 1.68B | 1.58B | 1.74B | |||||
Cost of Goods Sold, Total | 428M | 726M | 629M | 643M | 698M | |||||
Gross Profit | 836M | 1.25B | 1.05B | 938M | 1.04B | |||||
Selling General & Admin Expenses, Total | 338M | 397M | 393M | 432M | 493M | |||||
R&D Expenses | 118M | 137M | 154M | 174M | 198M | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 456M | 533M | 547M | 606M | 691M | |||||
Operating Income | 379M | 712M | 506M | 332M | 353M | |||||
Interest Expense, Total | -3.9M | -5M | -4.9M | -6.7M | -18.2M | |||||
Interest And Investment Income | 2.2M | 1.5M | 2.6M | 2.6M | 3.3M | |||||
Net Interest Expenses | -1.7M | -3.5M | -2.3M | -4.1M | -14.9M | |||||
Currency Exchange Gains (Loss) | -7.1M | 9.4M | 900K | -100K | -4.7M | |||||
EBT, Excl. Unusual Items | 370M | 718M | 504M | 328M | 334M | |||||
Asset Writedown | - | - | - | - | -98.1M | |||||
EBT, Incl. Unusual Items | 370M | 718M | 504M | 328M | 236M | |||||
Income Tax Expense | 83.2M | 194M | 127M | 77.7M | 103M | |||||
Earnings From Continuing Operations | 287M | 524M | 377M | 250M | 133M | |||||
Net Income to Company | 287M | 524M | 377M | 250M | 133M | |||||
Net Income - (IS) | 287M | 524M | 377M | 250M | 133M | |||||
Net Income to Common Incl Extra Items | 287M | 524M | 377M | 250M | 133M | |||||
Net Income to Common Excl. Extra Items | 287M | 524M | 377M | 250M | 133M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.5 | 0.91 | 0.65 | 0.43 | 0.23 | |||||
Basic EPS - Continuing Operations | 0.5 | 0.91 | 0.65 | 0.43 | 0.23 | |||||
Basic Weighted Average Shares Outstanding | 574M | 576M | 577M | 578M | 582M | |||||
Net EPS - Diluted | 0.5 | 0.9 | 0.65 | 0.43 | 0.23 | |||||
Diluted EPS - Continuing Operations | 0.5 | 0.9 | 0.65 | 0.43 | 0.23 | |||||
Diluted Weighted Average Shares Outstanding | 579M | 580M | 580M | 582M | 586M | |||||
Normalized Basic EPS | 0.4 | 0.78 | 0.55 | 0.35 | 0.36 | |||||
Normalized Diluted EPS | 0.4 | 0.77 | 0.54 | 0.35 | 0.36 | |||||
Dividend Per Share | 0.28 | 0.38 | 0.4 | 0.4 | 0.42 | |||||
Payout Ratio | 45.39 | 30.75 | 53.2 | 68.32 | 89.97 | |||||
American Depositary Receipts Ratio (ADR) | 10 | 10 | 10 | 10 | 10 | |||||
Supplemental Items | ||||||||||
EBITDA | 426M | 781M | 578M | 410M | 445M | |||||
EBITA | 387M | 724M | 577M | 351M | 375M | |||||
EBIT | 379M | 712M | 506M | 332M | 353M | |||||
EBITDAR | 426M | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 22.46 | 27.01 | 25.25 | 23.69 | 43.74 | |||||
Total Current Taxes | 107M | 253M | 134M | 70M | 92.8M | |||||
Total Deferred Taxes | -23.8M | -58.9M | -6.5M | 7.7M | 10.3M | |||||
Normalized Net Income | 232M | 449M | 315M | 205M | 209M | |||||
Interest Capitalized | 2.1M | - | 400K | 1.3M | 2.4M | |||||
Interest on Long-Term Debt | 3.9M | 1.6M | - | - | - | |||||
Non-Cash Pension Expense | - | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 118M | 137M | 154M | 174M | 198M | |||||
Net Rental Expense, Total | 900K | - | - | - | - | |||||
Imputed Operating Lease Interest Expense | 383K | - | - | - | - | |||||
Imputed Operating Lease Depreciation | 517K | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 6.1M | 7.7M | 8.1M | 9M | 10.8M | |||||
Total Stock-Based Compensation | 6.1M | 7.7M | 8.1M | 9M | 10.8M |